Pharmacologic Management of Hypertension in Patients on ACE Inhibitors Who Cannot Use Beta‑Blockers
First‑Line Combination Therapy
Adding a calcium‑channel blocker (CCB) or a thiazide‑like diuretic to an ACE‑inhibitor regimen is the guideline‑recommended first‑line strategy for uncontrolled hypertension in patients already receiving an ACE inhibitor. European Society of Cardiology (ESC) 2024 and American College of Cardiology/American Heart Association (ACC/AHA) 2025 guidelines support this approach. [1][2]
Amlodipine is the most extensively studied dihydropyridine CCB when combined with an ACE inhibitor and has demonstrated proven cardiovascular outcome benefits. ESC 2024 and ACC/AHA 2025 endorse its use. [1][2]
The combination of an ACE inhibitor plus a CCB is explicitly recommended by both the 2024 ESC and 2025 ACC/AHA guidelines as a preferred two‑drug regimen for hypertension. [1][2]
Chlorthalidone or indapamide are preferred over hydrochlorothiazide because they provide superior cardiovascular outcomes when added to an ACE inhibitor. ESC 2024 and ACC/AHA 2025 guidelines cite this preference. [1][2]
Preferred Triple‑Drug Strategy
When blood pressure remains uncontrolled after two agents, the optimal regimen is a three‑drug combination: ACE inhibitor + dihydropyridine CCB + thiazide‑like diuretic. This strategy is endorsed by ESC 2024 and ACC/AHA 2025 guidelines. [1][2]
Delivering the triple combination as a single‑pill formulation is recommended to improve medication adherence. ESC 2024 and ACC/AHA 2025 guidelines advise this practice. [1][2]
Resistant Hypertension Management
If hypertension persists despite optimal dosing of the three‑drug regimen and the patient’s estimated glomerular filtration rate (eGFR) is ≥ 45 mL/min/1.73 m², add spironolactone (a mineralocorticoid‑receptor antagonist). This is the strongest recommendation for resistant hypertension in both the 2025 ACC/AHA and 2024 ESC guidelines. [3][4]
Spironolactone is specifically recommended when patients cannot tolerate or have contraindications to beta‑blockers. ACC/AHA 2025 guideline. 3
If spironolactone is not tolerated, consider the following fourth‑line agents (each supported by either ACC/AHA 2025 or ESC 2024 guidelines):
Beta‑Blocker Use and Avoidance
Beta‑blockers should be reserved for patients with compelling indications such as angina, post‑myocardial infarction, heart failure with reduced ejection fraction, or the need for heart‑rate control. This recommendation is outlined in the 2024 ESC guidelines. [1][2]
Beta‑blockers are no longer considered first‑line therapy for uncomplicated hypertension, per the 2024 ESC guidelines. [1][2]
Drug Interactions, Monitoring, and Clinical Pitfalls
Co‑administration of two renin‑angiotensin system blockers (ACE inhibitor + ARB) is explicitly not recommended. ESC 2024 guidelines. [1][2]
Prior to adding additional antihypertensive agents, review all concomitant medications for agents that may interfere with blood‑pressure control (e.g., NSAIDs, decongestants). ACC/AHA 2025 guideline. 3
If hypertension remains resistant after optimal three‑drug therapy, screen for secondary causes of hypertension. ACC/AHA 2025 guideline. 3
When initiating spironolactone for resistant hypertension, ensure the patient’s eGFR is ≥ 45 mL/min/1.73 m² to minimize the risk of hyperkalemia and renal impairment. ACC/AHA 2025 guideline. 3